Zacks Investment Research upgraded shares of Amarin Corporation PLC (NASDAQ:AMRN) from a hold rating to a buy rating in a research report released on Tuesday morning. The firm currently has $4.00 price objective on the biopharmaceutical company’s stock.

According to Zacks, “Amarin Corporation plc is a global pharmaceutical group which develops innovative pharmaceutical products across a range of therapeutic areas utilizing its proprietary advanced oral and transdermal drug delivery technologies. “

Several other research firms have also recently commented on AMRN. BidaskClub raised Amarin Corporation PLC from a buy rating to a strong-buy rating in a research note on Thursday, July 6th. Jefferies Group LLC raised their price target on Amarin Corporation PLC from $5.00 to $7.00 and gave the stock a buy rating in a research report on Friday, June 30th. HC Wainwright restated a buy rating and issued a $10.00 price target on shares of Amarin Corporation PLC in a research report on Thursday, August 3rd. Finally, Cantor Fitzgerald restated a buy rating and issued a $10.00 price target on shares of Amarin Corporation PLC in a research report on Tuesday, September 26th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. Amarin Corporation PLC currently has a consensus rating of Buy and a consensus target price of $7.20.

Shares of Amarin Corporation PLC (AMRN) opened at 3.4501 on Tuesday. The stock has a 50 day moving average price of $3.27 and a 200 day moving average price of $3.32. The firm’s market cap is $934.26 million. Amarin Corporation PLC has a one year low of $2.65 and a one year high of $4.47.

Amarin Corporation PLC (NASDAQ:AMRN) last released its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.05) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.06) by $0.01. The firm had revenue of $44.95 million during the quarter, compared to analyst estimates of $40.35 million. The firm’s quarterly revenue was up 37.0% on a year-over-year basis. During the same period last year, the business posted ($0.07) earnings per share. On average, equities research analysts forecast that Amarin Corporation PLC will post ($0.21) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another domain, it was illegally copied and reposted in violation of US & international copyright law. The legal version of this story can be read at https://www.thecerbatgem.com/2017/10/06/amarin-corporation-plc-amrn-lifted-to-buy-at-zacks-investment-research.html.

Several large investors have recently bought and sold shares of AMRN. Wells Fargo & Company MN boosted its position in shares of Amarin Corporation PLC by 4.8% in the 1st quarter. Wells Fargo & Company MN now owns 32,801 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 1,500 shares during the last quarter. Ameriprise Financial Inc. boosted its position in shares of Amarin Corporation PLC by 0.9% in the 1st quarter. Ameriprise Financial Inc. now owns 395,769 shares of the biopharmaceutical company’s stock worth $1,266,000 after purchasing an additional 3,413 shares during the last quarter. Raymond James Financial Services Advisors Inc. boosted its position in shares of Amarin Corporation PLC by 1.4% in the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 143,650 shares of the biopharmaceutical company’s stock worth $460,000 after purchasing an additional 2,050 shares during the last quarter. Private Advisor Group LLC boosted its position in shares of Amarin Corporation PLC by 2.1% in the 1st quarter. Private Advisor Group LLC now owns 50,170 shares of the biopharmaceutical company’s stock worth $157,000 after purchasing an additional 1,032 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its position in shares of Amarin Corporation PLC by 27.1% in the 1st quarter. JPMorgan Chase & Co. now owns 35,590 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 7,580 shares during the last quarter. Institutional investors and hedge funds own 37.76% of the company’s stock.

Amarin Corporation PLC Company Profile

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Get a free copy of the Zacks research report on Amarin Corporation PLC (AMRN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Amarin Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin Corporation PLC and related stocks with our FREE daily email newsletter.